ResMed's Device Momentum Meets a Software Business That Still Hasn't Stabilized

ResMed (NYSE: RMD) reports fiscal third-quarter 2026 earnings after market close on April 30, 2026, with analysts expecting $2.79 per share on revenue of $1.42 billion. The medical device maker faces a critical test as investors assess whether its sleep apnea device momentum and digital health expansion can sustain double-digit growth amid a challenging environment for its residential care software segment.

Part 1: Earnings Preview

ResMed is a global leader in sleep and respiratory care, developing cloud-connected devices, masks, and digital health solutions for sleep apnea and chronic obstructive pulmonary disease (COPD) patients across 140 countries. The company operates two primary segments: Sleep and Breathing Health (devices and masks) and Residential Care Software (business management software for out-of-hospital care providers).

For the fiscal third quarter ending March 2026, analysts project earnings of $2.79 per share, representing 17.7% growth compared to $2.37 reported in the same quarter last year. The consensus revenue estimate of $1.42 billion implies 10% year-over-year growth, an acceleration from the 7.9% increase recorded in Q3 2025. Last quarter, ResMed delivered $2.81 per share, beating estimates by 4.46%.

Three key themes define this earnings story:

Device Portfolio Momentum: Investors are watching whether the combined availability of AirSense 10 and AirSense 11 sleep devices continues driving underlying global demand. The company's strategic mask portfolio expansion and innovations like the NightOwl home sleep apnea test have been critical growth drivers, with strong resupply trends and new patient setups supporting revenue across U.S., Canada, Latin America, Europe, and Asia-Pacific markets.

Digital Health Transformation: ResMed's integration of AI and machine learning into its digital health ecosystem—including the Dawn personal sleep health assistant within the myAir platform—represents a strategic shift toward software-driven recurring revenue. The VirtuOx acquisition is expected to contribute incremental revenues while expanding the company's home healthcare capabilities.

Residential Care Software Headwinds: The RCS segment faces a challenging growth environment in senior living and long-term care verticals, though management has been executing a portfolio optimization strategy to channel investment toward higher-margin platforms like MEDIFOX and core Brightree. Analysts expect this segment to grow approximately 6.8%, significantly slower than the device business.

Zacks Investment Research notes that ResMed carries a Zacks Rank #3 (Hold) with an Earnings ESP of +0.39%, suggesting a higher probability of beating estimates. The firm highlights that estimates have remained stable over the past 60 days, indicating analysts expect the business to "stay the course." Multiple analysts have maintained their projections, reflecting confidence in the company's execution despite macro headwinds.

Part 2: Historical Earnings Performance

ResMed has demonstrated consistent execution over the past four quarters, beating analyst estimates in all four reports with an average surprise of 2.74%. The company's beat rate and magnitude have been remarkably stable, suggesting strong operational predictability.

Looking at the progression, ResMed reported $2.37 in Q3 2025 (beating by 0.42%), $2.55 in Q4 2025 (beating by 3.66%), $2.55 in Q1 2026 (beating by 2.41%), and most recently $2.81 in Q2 2026 (beating by 4.46%). The sequential acceleration in both absolute earnings and beat magnitude—particularly the 4.46% surprise last quarter—indicates strengthening fundamentals and potentially conservative guidance from management.

The year-over-year comparison is equally compelling: the $2.79 consensus for the upcoming quarter represents 17.7% growth versus the $2.37 reported in Q3 2025, marking the strongest projected growth rate in this four-quarter window. This acceleration, combined with the company's perfect beat streak, suggests ResMed is executing well in a favorable demand environment for sleep and respiratory health solutions.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

ResMed reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

ResMed's post-earnings price behavior shows significant volatility with a strong upward bias. Over the past eight quarters, the stock has averaged an absolute Day +1 move of 6.72%, with a trading range averaging 6.71%—indicating substantial two-way action following results.

The most dramatic reactions have been positive: the stock surged 18.89% on Day +1 following the April 2024 report and jumped 10.10% after April 2025 earnings. However, volatility cuts both ways—ResMed dropped 8.33% following January 2025 results despite initially rising 1.89% on Day 0, demonstrating how initial reactions can reverse sharply.

Day 0 moves have been relatively muted (averaging 0.77%), which is typical for after-hours reporters where anticipatory positioning is limited. The 2.99% average Day 0 range suggests modest intraday volatility before the close. The pattern is clear: investors should expect the real price discovery to occur on Day +1, with historical precedent pointing to moves in the 5-10% range being common, and double-digit swings possible when results significantly surprise.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.66% expected move through the May 15 expiration, translating to a range of $193.57 to $230.29. This implied volatility of 53.41% is notably higher than the 6.72% average historical Day +1 move, suggesting options traders are pricing in elevated uncertainty—possibly reflecting concerns about guidance or macro factors beyond the quarterly results themselves. Investors should note that while history suggests a typical 5-7% post-earnings move, the options market is pricing roughly 30% more volatility than the historical average.

Part 3: What Analysts Are Saying

Analyst sentiment on ResMed remains constructive but cautious, with the consensus rating at 3.90 (between Hold and Buy) on the five-point scale. The $287.23 average price target implies 35.5% upside from the current price of $211.93, though estimates span a wide range from a low of $230.00 to a high of $345.00.

The analyst community is divided: 9 Strong Buys and 2 Moderate Buys are offset by 8 Hold ratings, 1 Strong Sell, and 0 Moderate Sells among the 20 analysts covering the stock. Notably, sentiment has improved over the past month, with the average recommendation rising from 3.84 to 3.90 and the number of Strong Buy ratings increasing from 8 to 9.

This upgrade activity suggests growing confidence in ResMed's growth trajectory, likely driven by the company's consistent earnings beats and accelerating revenue growth in its core Sleep and Breathing Health segment. The wide target range—spanning $115 from low to high—reflects differing views on how quickly the company can scale its digital health initiatives and whether the residential care software headwinds will prove transitory or structural. The improving sentiment trend, combined with the substantial implied upside to the mean target, indicates analysts see the recent pullback as a potential buying opportunity ahead of what could be another quarter of solid execution.

Part 4: Technical Picture

ResMed enters earnings in a decisively bearish technical posture, with the Barchart Technical Opinion registering a 100% Sell signal—a reading that has remained unchanged over the past week and month, indicating persistent selling pressure with no signs of stabilization.

Timeframe Analysis:

• Short-term (100% Sell): Maximum bearish signal reflects intense near-term downward momentum with no technical support
• Medium-term (100% Sell): Intermediate timeframe confirms the weakness is not just a short-term fluctuation but a sustained trend deterioration
• Long-term (100% Sell): Longer-term perspective shows the bearish structure extends across all time horizons, indicating a comprehensive breakdown in trend

Trend Characteristics: The signal exhibits Maximum strength in the Strongest direction, indicating an unambiguous and powerful downtrend across all timeframes heading into the earnings release.

The stock is trading at $211.93, positioned below every major moving average: the 5-day ($218.09), 10-day ($221.27), 20-day ($224.40), 50-day ($234.84), 100-day ($243.91), and 200-day ($256.17). This complete breakdown below all moving averages—with the stock now 17.3% below its 200-day—represents a classic bearish alignment where each shorter-term average sits below the next longer-term average, creating resistance layers overhead.

The technical setup heading into earnings is decidedly unfavorable, with RMD trapped in a well-defined downtrend and facing multiple resistance levels above. The nearest overhead resistance sits at the 5-day moving average around $218, followed by the 10-day at $221 and 20-day at $224. For bulls to regain control, the stock would need to reclaim at least the 20-day average and break the pattern of lower highs.

The 100% Sell signal with Maximum strength suggests any earnings-driven rally will face significant technical headwinds, while a disappointment could accelerate the existing downtrend. The 50-day moving average at $235 represents a critical inflection point—a move back above that level would be required to signal a meaningful trend reversal. Given the stock is trading more than 10% below that threshold, investors should view the technical backdrop as a cautionary factor that could amplify downside volatility if results or guidance disappoint.